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Angiogenesis, the process of new blood vessel formation
from pre-existing ones, plays a key role in various
physiological and pathological conditions, including
embryonic development, wound repair, inflammation, and
tumor growth [1]. The local, uncontrolled release of
angiogenic growth factors and/or alterations of the produc-
tion of natural angiogenic inhibitors, with a consequent
alteration of the angiogenic balance [2], are responsible for
the uncontrolled endothelial cell proliferation that takes
place during tumor neovascularization and in angiogenesis-
dependent diseases [3].
Angiogenesis is a multi-step process that begins with the
degradation of the basement membrane by activated
endothelial cells that will migrate and proliferate, leading
to the formation of solid endothelial cell sprouts into the
stromal space. Then, vascular loops are formed and capillary* Corresponding author. Tel.: +39 030 3717 311; fax: +39 030 3701 157.
E-mail address: presta@med.unibs.it (M. Presta).
1359-6101/$ – see front matter # 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.cytogfr.2005.01.004tubes develop with formation of tight junctions and
deposition of new basement membrane [4].
Numerous inducers of angiogenesis have been identified,
including the members of the vascular endothelial growth
factor (VEGF) family, angiopoietins, transforming growth
factor-a and -b (TGF-a and -b), platelet-derived growth
factor (PDGF), tumor necrosis factor-a (TNF-a), inter-
leukins, chemokines, and the members of the fibroblast
growth factor (FGF) family.
Historically, a tumor angiogenic factor (TAF) was first
isolated in 1971 from rat Walker 256 carcinoma [5]. TAF had a
molecular weight of about 10 kDa and consisted of 25% RNA,
10% proteins, and 58% carbohydrates, plus a possible lipid
fraction. The 1980s saw for the first time the purification to
homogeneity of pro-angiogenic proteins, the breakthrough
coming as a result of the observation that endothelial cell
growth factors showed a marked affinity for heparin [6,7]. This
led to the identification, purification, and sequencing of the
two prototypic heparin-binding angiogenic growth factors
FGF1 and FGF2. Since then, 22 structurally-related members
of the FGF family have been identified [8]. FGFs are
pleiotropic factors acting on different cell types, including
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proteoglycans (HSPGs) and tyrosine kinase FGF receptors
(FGFRs). To date, more than 1200 PubMed-referenced papers
related to FGFs and FGFRs in endothelial cells and during
neovascularization have been published. This review will
focus on the role of the FGF/FGFR system in angiogenesis.2. Pro-angiogenic activity of FGFs
As stated above, FGFs exert their biological activities by
binding to high affinity tyrosine kinase FGFRs on the
surface of target cells. In vitro, endothelial cells of different
origin express FGFR1 [9,10] and, under some circum-
stances, FGFR2 [11] whereas the expression of FGFR3 or
FGFR4 has never been reported in endothelium.
Only a limited number among the 22 members of the FGF
family have been investigated for their angiogenic potential
in vitro and in vivo, the bulk of experimental data referring to
the prototypic FGF1 and FGF2.
2.1. In vitro effects on endothelial cells
The necessity to study in detail the process of
angiogenesis has led to the isolation and in vitro culture
of endothelial cells [12]. A high degree of heterogeneity has
been observed for endothelial cells isolated from different
tissues and/or animal species. Also, significant differences
exist between large-vessel and microvascular endothelium
[13–15]. Nevertheless, the bulk of experimental evidence
indicate that different members of the FGF family, mostly
FGF1 and FGF2, can induce in vitro a complex ‘‘pro-
angiogenic phenotype’’ in endothelial cells (Fig. 1) that
recapitulates several aspects of the in vivo angiogenesis
process, including the modulation of endothelial cell
proliferation, migration, protease production, integrin and
cadherin receptor expression, and intercellular gap-junction
communication (summarized in [10]).Fig. 1. Schematic representation of the events triggered by FGFs in endothelial cell
neovascularization in vivo.2.1.1. Endothelial cell proliferation
Activation of FGFR1 or FGFR2 by angiogenic FGFs
(including FGF1, FGF2, and FGF4) leads to endothelial cell
proliferation [16]. Recently, also the FGF8b isoform has
been shown to stimulate endothelial cell proliferation in
vitro [17]. FGFR engagement involves the activation of
several parallel signaling pathways as a consequence of
receptor autophosphorylation followed by recruitment of
Shc, FRS2, and Crk adaptor molecules (for a review see
[16]). Interestingly, besides activation of the MAPK
signaling pathway, a long lasting activation of protein
kinase C (PKC) is required for FGF2 to exert a full
mitogenic response in endothelial cells [18]. PKC down-
regulation abolishes FGF2-induced endothelial cell prolif-
eration but not urokinase-type plasminogen activator
(uPA) upregulation. Also, autophosphorylation of distinct
tyrosine residues in FGFR1 mediate the mitogenic and uPA-
inducing activity of FGF2 [19], suggesting that the two
biological responses can be dissociated at the molecular
level.
2.1.2. Extracellular matrix degradation
Extracellular matrix (ECM) degradation represents an
important step during the first phases of the angiogenesis
process. The plasmin–plasminogen activator system and
matrix metalloproteinases (MMPs) cooperate in this
degradation [20]. uPA converts plasminogen into plasmin,
a serine protease that degrades fibrin and other matrix
proteins, and activate several MMPs, including stromelysin-
1 (MMP-3), collagenase-1 (MMP-1), type IV collagenases
(MMP-2 and MMP-9) [21].
FGF1, FGF2, and FGF4 upregulate uPA and MMPs
production in endothelial cells. Also, FGFs modulate the
expression of uPA receptor on the endothelial cell surface,
thus allowing the localization of the proteolytic activity at
the leading edge of the cell at the front of migration [22].
Furthermore, FGF1 and FGF2 induce the expression of
the plasminogen activator inhibitor (PAI)-1 in cultureds that contribute to the acquisition of the angiogenic phenotype in vitro and to
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proteolytic balance [23–25].
Stimulation of endothelial cells by FGF2 causes also the
shedding of cell surface membrane vesicles containing
MMP-2 and MMP-9 together with the two MMP inhibitors
TIMP-1 and TIMP-2. These vesicles stimulate capillary-like
structure formation when added to endothelial cells seeded
on a solubilized basement membrane preparation (Matrigel)
[26].
2.1.3. Endothelial cell migration
FGF1 and FGF2 [27,28], the FGF8b isoform [17], and
FGF10 [29] stimulate chemotaxis and/or chemokinesis in
endothelial cells. Similar to cell proliferation, the
chemotactic effect of FGF2 requires the activation of the
MAPK signaling pathway [30] and is abolished by PKC
down-regulation [31]. The capacity of FGFR1 to mediate
chemotaxis resides in the amino acid stretch 759–773 of its
cytoplasmic tail [32]. However, the biological response is
independent of tyrosine phosphorylation and requires the
activation of a Wortmannin-sensitive pathway [32].
Expression of a kinase-inactive c-Fes mutant interferes
with FGF2-induced chemotaxis in endothelial cells [33].
Moreover, FGF2-mediated chemotaxis on fibronectin-
coated substrata can be attenuated by avb3 integrin
inhibitors [34].
The angiogenesis process can be mimicked in vitro by
culturing endothelial cells on a layer of or within a 3D
permissive matrix substrate [35]. Under these conditions,
endothelial cells invade the substratum and organize
capillary-like structures with a hollow lumen [36]. FGF2
enhances this response in type I collagen gel [37] possibly
via a p38-dependent signaling pathway [38]. Endothelial
cell morphogenesis can be induced by FGF2 also using
three-dimensional fibrin gels [39]. Invasion of fibrin matrix
can be modulated by TGF b-1 [39,40] and is mediated by
CD44 [41] and integrin receptors [42].
2.1.4. Modulation of integrins, cell–cell adhesion
receptors, and matrix deposition
Endothelial cell migration and proliferation are limited
by lateral cell–cell adhesion and ECM interactions [43] that,
in turn, are mediated by cadherin and integrin receptors.
Accordingly, FGF2-mediated adhesion and migration of
endothelial cells onto type I collagen depends on both
integrin expression and cell density [44]. Interestingly,
FGF2 regulates the expression of different integrins,
including avb3 [45–47], and cadherins [43,48] in a complex
fashion. Indeed, a brief exposure to FGF2 hampers
endothelial cell–cell junctions whereas a prolonged expo-
sure to the growth factor promotes a slow temporal re-
distribution of the junctional adhesion proteins, platelet/
endothelial cell adhesion molecule (PECAM/CD31), vas-
cular/endothelial cadherin, and plakoglobin. These data
indicate that FGFs can promote both endothelial cell
scattering, that is required during the first steps of theangiogenic process, and the formation of the cell–cell
interactions required to vessel maturation [43] (Fig. 1). A
similar mechanism of regulation may exist also for the
interaction with the ECM that surrounds the endothelium.
Indeed, FGFs initially promote the disruption of the basal
lamina by inducing protease production. Lately, FGFs may
induce the production of various ECM components by
endothelial cells [49], contributing to the maturation of the
new vessels (Fig. 1).
2.1.5. Endothelial cell morphogenesis
FGF2 [50] and FGF8b [17] can enhance endothelial cell
reorganization on Matrigel. The process requires the activation
of the proteolytic machinery, including type IV collagenase(s)
and TIMPs production [51] as well as uPA and PAI-1
upregulation [52], a6b1 integrin receptor engagement [53],
PECAM-1 [54], and activation of the small GTPase Rac [55].
Moreover, FGF2-mediated endothelial cell morphogenesis
requires signals via VEGF receptor-1 (VEGFR-1) [56],
underlying the cross-talk between FGF and VEGF signaling
(see below).
2.1.6. Autocrine, intracrine, paracrine mechanisms of
action of FGFs in endothelial cells
FGFs can exert their effects on endothelial cells via a
paracrine mode consequent to their release by tumor and
stromal cells and/or by their mobilization from the ECM. On
the other hand, FGF2 may also play an autocrine role in
endothelial cells, as suggested by in vitro and in vivo
experimental evidences (see [57] and references therein).
Accordingly, FGF2 has been implicated in the pathogenesis of
lesions of endothelial cell origin, including Kaposi’s sarcoma
[58] and hemangiomas [59]. Also, the fgf4 gene is over-
expressed in HHV8-positive Kaposi’s sarcoma [60]. To assess
the biological consequences of endothelial cell activation by
endogenous FGFs, we originated a stable mouse aortic
endothelial cell line transfected with a human FGF2 cDNA
[57]. FGF2 transfectants show an invasive and morphogenetic
behavior in vitro. In vivo, they are angiogenic, cause the
formation of opportunistic vascular tumors in nude mice, and
induce hemangiomas in the chick embryo [61]. Accordingly,
FGF2 transfection affects the expression of numerous genes
implicated in the modulation of cell cycle, differentiation, cell
adhesion, and stress/survival [62]. Some of these genes are
similarly modulated in vitro and in vivo by administration of
the recombinant growth factor [62].
A transformed morphology and an increased proliferative
capacity is also observed for FGF4-transfected mouse aortic
endothelial cells. However, FGF4 transfectants, although
angiogenic in the chorioallantoic membrane (CAM) assay,
show a limited capacity to growth under anchorage-
independent conditions, to invade 3D fibrin gel, to undergo
morphogenesis in vitro, and to induce hemangiomas in the
chick embryo [11].
The observed differences between FGF2 and FGF4
transfectants may reflect differences in the intracellular and/
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copy human fgf2 gene encodes multiple FGF2 isoforms with
molecular weight ranging from 18 to 24 kDa. Both low and
high molecular weight FGF2 isoforms show angiogenic
activity [63]. At variance with other FGFs, FGF2 isoforms
lack a leader sequence for secretion and are released in
limited amounts by an alternative secretion pathway [64] or
via membrane vesicle shedding [65]. Experimental evi-
dences point to different functions of FGF2 isoforms in
transfected endothelial cells [66], possibly related to
differences in their subcellular localization and release.
Indeed, high molecular weight FGF2 isoforms contain a
nuclear localization sequence and are mostly recovered in
the nucleus whereas the 18 kDa FGF2 isoform is mostly
cytosolic [67]. The constitutive overexpression of high
molecular weight FGF2 isoforms leads to cell immortaliza-
tion whereas 18 kDa FGF2 overexpression induces a
transformed phenotype [68]. In contrast, FGF4 is efficiently
released and does not play an intracellular role [69]. On this
basis, the biological differences observed between FGF2 and
FGF4 endothelial cell transfectants may reflect differences
in the intracrine and/or autocrine activities of the two growth
factors. Accordingly, transfection with a secreted form of
FGF1 leads to altered morphology and increased motility in
endothelial cells [70].
Taken together, these data suggest that endogenous FGFs
produced by endothelial cells may play important autocrine,
intracrine, or paracrine roles in angiogenesis and in the
pathogenesis of vascular lesions.
2.2. In vivo effects and experimental angiogenesis assays
FGFR1 is expressed by endothelial cells in vivo [71–73],
even though a detailed analysis of FGFR expression patterns
in vivo deserves further investigation. To this respect,
disruption of the genes encoding for the different FGFRs in
mice is not informative. Indeed, fgfr1 null embryos are
developmentally retarded and dye during gastrulation, the
early embryonic lethality occurring prior to a stage in which
the role of FGFR1 in blood vessel development can be
evaluated [74,75]. However, adenovirus-mediated expres-
sion of dominant-negative FGFR1 results in a significant
impairment of blood vessel development and maintenance in
mouse embryos cultured in vitro [76]. Fgfr2 mutation results
in a later embryonic lethality characterized by the lack of a
functional placenta and limb buds [77]. Fgfr3-deficient mice
are normal during gestation and exhibit bone alterations
during postnatal development [78]. Finally, Fgfr4-null
animals are developmentally normal [79].
In keeping with the expression of FGFR1 on endothelial
cells in vivo, the angiogenic activity of recombinant FGF1
and FGF2 proteins has been demonstrated in various
experimental models, including the chick embryo CAM
[80], the avascular rabbit [81] or mouse [82] cornea, and
subcutaneous Matrigel injection [83]. Similarly, the delivery
of either one of the two growth factors via retroviral,adenoviral, lentiviral, and adeno-associated viral vectors or
via implantation of different FGF-overexpressing cell
transfectants result in a potent angiogenic response in
various experimental animal models (see below).
The CAM assay is a well-established assay for studying
the effects of growth factors on blood vessel growth [80]. As
compared to the application on the CAM of a single bolus of
recombinant FGF2, cell implants overexpressing the growth
factor allows the continuous delivery of FGF2 produced by a
limited number of cells, thus mimicking more closely the
initial stages of tumor angiogenesis [84]. Indeed, the release
of 1.0 pg FGF2 per day from viable cells triggers an
angiogenic response quantitatively similar to that elicited by
1.0 mg of the recombinant molecule [84]. Also, neutralizing
anti-FGF2 antibodies prevent CAM neovascularization,
supporting the key role of endogenous FGF2 in the
development of vascular system in avian embryo [85].
Accordingly, FGFRs are expressed in the CAM until E10,
when the angiogenic process is switched off [86].
In contrast with the potent angiogenic response elicited
by exogenous FGF2 in different in vitro and in vivo models,
the role of endogenous FGF2 in angiogenesis remains
uncertain. Indeed, fgf2 knockout mice are morphologically
normal [87] and do not show differences in neovasculariza-
tion following injury [88] or hypoxia [89]. Conversely,
transgenic overexpression of FGF2 does not result in
spontaneous or inherent vascular defects, even though an
amplified angiogenic response can be observed after
wounding or s.c. implantation of a Matrigel plug [90].
The apparently normal vascularization in fgf2/ mice as
well as in double fgf2//fgf1/ mice may reflect the wide
redundancy in the FGF family [91] and the contribution to
angiogenesis of several other angiogenic growth factors,
including VEGF (see below).
Angiogenic activity has been shown also for other
members of the FGF family. FGF3/int-2 oncogene expres-
sing human epithelial mammary cells or their conditioned
culture medium exert a potent angiogenic response in the
CAM assay. The same conditioned medium triggers
angiogenesis also in the mesentery of i.p. injected rats
[92]. Analysis of mammary glands from fgf4 transgenic
mice confirmed preliminary in vitro data about the
angiogenic properties of FGF4 mediated through VEGF-
A upregulation [93]. The pro-angiogenic activity of FGF4 is
confirmed by the angiogenic effect exerted by FGF4-
encoding adenovirus in a rabbit hind limb ischemia model
[94] and by FGF4-transfected endothelial cells in the CAM
assay [11]. Intracoronary gene transfer of FGF5 increases
blood flow and contractile function in ischemic heart
possibly related to an increased vascularization [95].
Subnanomolar concentrations of FGF7/KGF induce neo-
vascolarization in the avascular rat cornea [29]. FGF8b
elicits an angiogenic response in the CAM assay [17]
significantly enhanced by heparin co-administration (Presta,
unpublished observations). Transient expression of FGF9 in
transgenic mice results in alterations of retinal pigment
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vasculature [96]. Finally, FGF10, which is structurally
related to FGF7, elicits a pro-migratory effect on capillary
endothelial cells, suggesting a possible pro-angiogenic
activity in vivo [29].
2.3. FGF/VEGF cross-talk
For many years FGF1 and FGF2 occupied a central stage
in the angiogenesis field. Then, the VEGF family of
angiogenic growth factors came to the limelight after the
discovery of their pivotal role in vasculogenesis and
angiogenesis during embryonic development and under
numerous physiologic and pathologic conditions in adults
[97]. The VEGF family comprises six members (VEGF-A
denoting the originally identified VEGF) that differently
interact with three cell surface tyrosine kinase VEGFRs. To
date, VEGF-A/VEGFR-2 interaction appears to play a major
role in blood vessel angiogenesis whereas VEGF-C and -D
are mainly involved in lymphangiogenesis by interacting
with VEGFR-3 expressed on lymphatic endothelium [97].
An intimate cross-talk exists among FGF2 and the
different members of the VEGF family during angiogenesis,
lymphangiogenesis, and vasculogenesis. Several experi-
mental evidences point to the possibility that FGF2 induces
neovascularization indirectly by activation of the VEGF/
VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit
both VEGF and FGF2-induced angiogenesis in vitro and in
vivo [98]; (ii) expression of dominant-negative FGFR1 or
FGFR2 in glioma cells results in a decrease in tumor
vascularization paralleled by VEGF down-regulation [99];
(iii) both endogenous and exogenous FGF2 modulate VEGF
expression in endothelial cells [82]; (iv) in the mouse cornea,
the quiescent endothelium of vessels of the limbus express
both VEGF mRNA and protein only after FGF2 treatment.
In the same model, systemic administration of anti-VEGF-A
neutralizing antibodies dramatically reduces FGF2-induced
vascularization [82]; (v) VEGFR-1-blocking antibodies or
the expression of a dominant-negative VEGFR-1 result in a
significant reduction of FGF2-induced cell extensions and
capillary morphogenesis [56]; (vi) FGF2 upregulates the
expression of both FGFRs and VEGFRs in endothelial cells
[100].
On the other hand, endothelial cell tube formation
stimulated by VEGF in murine embryonic explants depends
on endogenous FGF2 [101]. Also, FGF2 and VEGF may
exert a synergistic effect in different angiogenesis models
[102–104] even though this may not be the case when the
two factors are applied onto the chick embryo CAM [105].
Recently, we analyzed the vascularization of xenografts
originating from different clones of the same human tumor
cell line but differing for the expression of VEGF and/or
FGF2 [106]. The two growth factors exert a synergistic
effect on tumor blood vessel density. However, FGF2 and
VEGF exert a different impact on blood vessel maturation
and functionality (see below). Accordingly, the study of thetranscriptional changes occurring in cultured endothelial
cells revealed that, together with a cluster of angiogenesis-
related genes that were similarly modulated by FGF2 and
VEGF, the two growth factors affected the expression of
distinct subsets of transcripts [107,108]. Accordingly, FGF2,
but not VEGF, induces the upregulation of telomerase
activity in endothelial cells, thus preventing the early onset
of senescence [109]. Distinct patterns of vascular morphol-
ogy upon FGF2 or VEGF stimulation are described also in
the quail embryo CAM assay [86]. Finally, increased
endothelial fenestration is observed in the blood vessels of
the chick embryo CAM stimulated by VEGF-overexpres-
sing cells, but not by FGF2-overexpressing cells, despite the
quantitatively similar angiogenic response elicited by the
two transfectants [84].
Thus, FGF2 may require the activation of the VEGF/
VEGFR system for promoting angiogenesis. Conversely,
VEGF may require FGF2 for exerting its angiogenic
potential under defined experimental conditions. Never-
theless, the two growth factors retain distinct biological
properties exerting different biological effects on endothe-
lial cells during angiogenesis.
Lymphatic system drains extravasated fluid, proteins, and
immune cells, and transport them back to the venous
circulation via the collecting lymphatic vessels and the
thoracic duct. In tumors the development of the lymphatic
network may play a critical role in facilitating the metastatic
spread of malignant cells. Recent data demonstrate that a
FGF/VEGF cross-talk may occur also during lymphangio-
genesis. FGF2 pellets implanted in the mouse cornea trigger
both angiogenesis and lymphangiogenesis, lymphatic
vessels being more sensitive than blood vessels to FGF2
[110]. However, the lymphangiogenic activity of FGF2 is
mediated by endogenous VEGF-C and VEGF-D upregula-
tion, leading to VEGFR-3 activation [111]. Interestingly, no
endothelial fenestration was observed in FGF2, VEGF-A, or
VEGF-C-induced lymphatic vessels [112].
The VEGF/VEGFR system is essential for the develop-
ment of embryonic vasculature [113]. The situation is much
less well-defined for the FGF/FGFR system. As stated
above, the phenotype of fgfr knockout mice is scarcely
informative even though adenovirus-drive dominant-nega-
tive FGFR1 expression leads to severe vascular alterations in
mouse embryos [76]. Also, FGF2 promotes the proliferation
and differentiation of VEGFR-2+ hemangioblast precursors
from the mesoderm [114]. In embryoid bodies, embryonic
stem cells can differentiate into a variety of cell lineages,
including endothelial cells [115]. In this model, both VEGF
and FGF2 lead to improved angioblast survival but only
VEGF supports the formation of primitive endothelial tubes
[116]. Also, in embryoid bodies in which VEGF/VEGFR
function is impaired, FGF2 stimulates the formation of
endothelial cell clusters that fail to develop into primitive
vessels. In contrast, VEGF induces the formation of a
characteristic vascular plexus also in fgfr1/ embryoid
bodies [117].
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extracellular matrix, and free molecules
As stated above, FGFs interact with signaling FGFRs
expressed on the endothelial cell surface. However, various
other binding partners can affect the biological activity and
angiogenic potential of FGFs (Fig. 2). These molecules can
interact with FGFs in the extracellular environment, thus
modulating their bioavailability, stability, local concentra-
tion, interaction with endothelial receptors, and intracellular
fate. The complexity of this network of interactions is
manifold: (i) FGF-binding molecules, heterogeneous in
nature, are present in the blood stream or in body fluids as
free molecules or associated to ECM; (ii) under different
conditions, certain FGF-binding molecules may be present
as free, ECM-associated, or cell membrane-associated
molecules, possibly exerting different effects on FGF
activity (see below); (iii) endothelial cell receptors distinctFig. 2. FGF2-binding molecules. (A) Proteins, polysaccharides, and lipids
present as free molecules in body fluids, associated to ECM, or anchored to
endothelial cell membrane bind FGF2. Some of these molecules can change
their status from an immobilized to a free form (arrows) exerting opposite
effects on the biological activity of FGFs. (B) Some FGF binders are also
able to interact with FGF-binding sites/receptors present on the surface of
endothelial cells, possibly exerting agonist/antagonist effects (see text for
further details).from FGFRs may activate signal transduction pathways
complementary to those activated by FGFRs; (iv) some
FGF-binding molecules can also bind FGFRs, leading to
possible agonist/antagonist effects.
FGF2 is present in blood at concentrations equal to
0.6 pM in physiological conditions and up to 6.0 pM under
different pathological conditions [see [118] and references
therein] whereas its binding partners are present at
concentrations that are up to 1,000,000 times higher
(Table 1). Thus, FGFs should exist mainly as immobilized
molecules bound to the ECM and/or cell surface or as
circulating complexes. The relative concentrations of the
various FGF-binders may change greatly during different
physio-pathological conditions, shifting the binding of FGFs
from one ligand to another with repercussion on their
bioavailability, endothelial cell interactions, and biological
activities. Since the bulk of experimental data refer to the
interaction of FGF2 with a number of extracellular
molecules other than FGFRs, we will focus on FGF2 and
its binding partners, even though many of the interactions
described below may apply also to other members of the
FGF family and, possibly, to other cytokines.
3.1. Cell surface and ECM components
3.1.1. Heparin and HSPGs
FGFs are heparin-binding proteins. Heparin is a
negatively charged glycosaminoglycan released in the blood
stream during inflammation. However, FGFs are more likely
to interact with the heparan sulfate glycosaminoglycan
chains attached to HSPG core proteins. HSPGs are
expressed on the surface of almost all the cell types,
including the endothelium, where they can be found as
membrane-associated receptors, as ECM components, or
released as free molecules [119]. HSPGs modulate
angiogenesis by interacting with pro and negative regulators
[120]. In particular, heparin/HSPGs bind FGF1, FGF2,
FGF4, FGF7, and FGF8, modulating their biological
activities in vitro and in vivo [121]. The interaction of
heparin/HSPGs with FGFs occurs with low affinity and is
mediated by the negatively charged sulfated groups of the
saccharidic chain [122] that bind to basic amino acid motifs
[123].
The alternative binding of FGFs to heparin, or to free,
ECM-associated, or cell-surface HSPGs results in a fine
control of the bioavailability and endothelial cell interaction
of these growth factors (reviewed in [121]). In general, free
heparin/HSPGs sequester FGFs in the extracellular envir-
onment and act as FGF antagonists. On the contrary, cell-
associated HSPGs can directly activate a signal transduction
pathway in response to FGF2 [124], promote FGF2
internalization [125,126], and are required for a correct
presentation of FGFs to FGFRs, leading to the formation of
productive HSPGs/FGF/FGFR ternary complexes [121].
Finally, HSPGs of the ECM act as a reservoir for FGF2 that
reaches higher local concentrations and sustains the long-
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Table 1
FGF2-binding molecules
Endothelial cell surface receptors FGF2 affinity (Kd) Reference Number per cell Reference
FGFR 20.0 pM [125] 10–20,000 [125]
avb3 integrin 6.5 nM
b 1  106c [141]
HSPGsa 413.0 nM [125] 0.5–1.0  106d [125]
Gangliosides 3.0 nM [148] N.D.
Free molecules FGF2 affinity (Kd) Reference Blood concentration Reference
FGF-binding protein 10 nM [153] N.D.
Free gangliosides 6.0 mM [147] 10 mMe [249]
Heparin 42.0 nM [139] N.D.
TSPa 30.0 nM [150,151] 0.26–15.0 nMf [250]
PTX3a 10.0 nM [166] 0.16–0.36 nMg [251]
Fibrin(ogen)a 1.3–260.0 nMh [252] 7.0 mM [118]
a2 macroglobulin 62.0 nM [162] 5.0 mM [162]
xcFGFR1a 5.0–10.0 nM [158] N.D.
PDGF 23.0 nM [168] 74.0–204.0 nMi [253]
PF4 37.0 nM [170] 5.0–8.7 nMj [254]
Affinity of different FGF2-binding partners, their number per cell or their blood concentration are indicated. Please note that FGF2 concentration in blood may
range between 0.6 and 6.0 pM (see text). N.D.: not determined.
a These molecules can also be found associated to ECM.
b Our unpublished data.
c Value calculated by using radiolabeled fibronectin.
d These values refer to the number of FGF2-binding sites, as a single HSPG receptor can bind multiple FGF2 molecules.
e Total serum sialic acid content in healthy subjects.
f Values measured in the absence or in the presence of platelet activation.
g Values measured in the absence or in the presence of acute myocardial infarction.
h The two values are representative of the biphasic nature of the binding.
i Values measured in healthy and tumor-bearing individuals.
j Values measured in health and coronary disease.term stimulation of endothelial cells [127]. A schematic
representation of the effects exerted by the heparin/HSPGs
system on the biology of FGFs is shown in Fig. 3.
The binding of FGFs to different HSPGs may have
different biological consequences. This is the case for
syndecan, betaglycan, and perlecan, all able to bind FGF2
but with different effects. For instance, syndecan inhibits the
mitogenic activity of FGF2 whereas perlecan promotes
FGF2-induced cell proliferation and angiogenesis (reviewed
in [128]). It is interesting to note that modifications of
HSPGs composition can regulate the sensitivity of the cell to
different FGFs [129] and that FGFs themselves can
modulate HSPG synthesis [130].
Also, FGF2 regulates the synthesis of HSPGs as well as
the production of protease/glycosidase that digest the core
protein/saccharidic chains of HSPGs inducing the mobiliza-
tion of free HSPGs/HS chains [131]. ECM degradation can
lead to mobilization of entrapped FGF2 with consequent
activation of an angiogenic response [132].
The capacity of various angiogenic factors, including
FGFs, to bind heparin/HS indicates that molecules able to
interfere with this interaction may act as angiogenesis
inhibitors. The ability of low molecular weight heparin
fragments to reduce the angiogenic activity of FGF2 and
VEGF support this hypothesis. On this basis, several heparin-
like anionic molecules and heparin derivatives have been
developed as possible candidate drugs (reviewed in [128]).3.1.2. Integrin receptors
Integrins are transmembrane, adhesion receptor hetero-
dimers comprised of a and b subunits. The combination of
different subunits originates distinct integrins that mediate
cell adhesion to a variety of adhesive proteins of the ECM
[133]. Integrins regulates also the response of endothelial
cells to soluble growth factors, including FGF2 [134], but
the molecular mechanism(s) of this regulation are not fully
elucidated. avb3 integrin is expressed on endothelial cells
where it plays a central role in neovascularization. For this
reason it has been considered as a target for the development
of anti-cancer therapies [135].
Similar to classical adhesive proteins, FGF2 binds avb3
[136]. Consequently, immobilized FGF2 promotes endothe-
lial cell adhesion and spreading, leading to uPA upregula-
tion, cell migration, proliferation, and morphogenesis [137].
avb3/FGF2 interaction and endothelial cell adhesion to
immobilized FGF2 lead to the assembly of focal adhesion
plaques containing avb3 and FGFR1, whose presence is an
absolute requirement for the activation of ERK1/2 and cell
proliferation [137]. Accordingly, a direct avb3/FGFR1
interaction is required for a full response to FGF2 [138].
Endothelial cell adhesion and activation by immobilized
FGF2 may have relevance in vivo. Indeed, as stated above,
FGF2 accumulates as an immobilized protein in the ECM,
mainly by binding to HSPGs. Relevant to this point, heparin-
bound FGF2 retains it cell-adhesive capacity [139]. Also,
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Fig. 3. Biological consequences of FGF/HSPG interaction. (A) FGF bound to free heparin/HSPGs is sequestered in the extracellular environment. (B) FGF
binds to HSPGs of the endothelial cell surface, increasing its concentration in the microenvironment. (C) HSPGs promote FGF oligomerization that, in turn,
triggers FGFRs dimerization and signal transduction (D) that can be activated also by a direct FGF/HSPG interaction (E). (F) HSPGs mediate cell internalization
of FGF and, possibly, its nuclear delivery (G). (H) HSPGs of the ECM can present FGF to endothelial cell integrins to mediate substrate-adhesion.HSPGs bound to fibronectin present FGF2 in a biologically
active form [140]. Thus, HSPGs may facilitate the
interaction of ECM components with FGF2 that, in turn,
promotes endothelial cell adhesion and activation via avb3
(Fig. 3).
Integrin avb3 is expressed also at the luminal aspect of
endothelium [141] suggesting that it may also mediate the
biological affects exerted by free FGF2. Actually, anti-avb3
antibodies [136] and RGD- or DGR-containing peptides
[142] inhibit mitogenesis and protease upregulation trig-
gered by free FGF2 in cultured endothelial cells. Accord-
ingly, RGD-peptidomimetic inhibits FGF2-dependent
neovascularization in the CAM assay and tumorigenesis
in vivo [143].
3.1.3. Gangliosides
Gangliosides are neuraminic acid (NeuAc)-containing
glycosphingolipids. Under physiological conditions, gang-
liosides are mainly associated to the membrane of different
cell types, including endothelium, where they modulate cell
growth, adhesion, and cell–cell interaction [144]. During
tumor growth and metastatization, gangliosides shed in the
microenvironment [145] with a consequent increase of their
serum levels (Table 1) and accumulation in the tumor
microenvironment. For instance, gangliosides are highly
expressed in the hyper-vascularized areas of gliomas where
they regulate angiogenesis [146].
Gangliosides bind FGF1, FGF2, and FGF4 via negatively
charged Neu-Ac residues [147,148]. In the extracellular
environment, gangliosides compete with free heparin for thebinding to the growth factor. On endothelial cells, free
gangliosides prevent the binding of FGF2 to FGFRs and
HSPGs, thus inhibiting FGF2-mediated cell proliferation
[147].
Ganglioside GM1 is expressed on the endothelial cell
surface and binds FGF2 with an affinity that is significantly
higher than that of its free counterpart (Table 1). Under these
conditions, GM1 acts as a functional FGF2 co-receptor.
Indeed, inhibitors of ganglioside synthesis or GM1-binding
cholera toxin b-subunit impair the capacity of endothelial
cells to proliferate when stimulated by FGF2. On the
contrary, GM1 overloading of the cell membrane increases
the responsiveness of endothelial cells to FGF2 [148].
3.1.4. Thrombospondin-1
Thrombospondin-1 (TSP-1) is a modular glycoprotein
secreted by different cell types, including endothelial cells.
It is composed of multiple active domains that bind to
soluble factors, cell receptors, and ECM components [149].
In particular, TSP-1 associates to HSPGs of the ECM and
binds integrin receptors [149]. TSP-1 was the first
endogenous inhibitor of angiogenesis to be identified and
its effect is due, at least in part, to its capacity to bind FGF2
[150]. The interaction is mediated by the COOH-terminal,
anti-angiogenic 140 kDa fragment of TSP-1. TSP-1 prevents
the interaction of FGF2 with soluble heparin and with
endothelial cell HSPGs and FGFRs. Accordingly, TSP-1
inhibits the mitogenic and chemotactic activity of FGF2 in
endothelial cells. TSP-1 also prevents the accumulation of
FGF2 in the ECM and favors the mobilization of matrix-
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[151]. These observations suggest that free TSP-1 can act as
a scavenger for matrix-associated FGFs, affecting their
location, bioavailability and function, whereas ECM-
associated TSP-1 may act as a ‘‘FGF decoy’’, sequestering
the growth factor in an inactive form.
3.1.5. Fibstatin
Fibstatin is a fibronectin fragment that binds FGF2 but
not FGF1, FGF3, FGF6, or FGF12 [152]. Fibstatin inhibits
FGF2-dependent proliferation, migration and tubulogenesis
of endothelial cells in vitro and angiogenesis and tumor
growth in vivo with high efficiency [152]. Like other FGF-
binding partners (see above), fibstatin is endowed of the
capacity to bind heparin and integrin receptors, suggesting
that multiple interactions are responsible for the anti-
angiogenic activity of this molecule.
3.1.6. FGF-binding protein
FGF-binding protein (FGF-BP) is a secreted protein that
binds FGF1 and FGF2 [153]. FGF-BP may act as a
chaperone molecule that competes with HSPGs for growth
factor binding and mobilizes FGFs from ECM, thus
facilitating their interaction with FGFRs. FGF-BP can serve
as an angiogenic switch for different tumor cell lines,
including squamous cell carcinoma and colon cancer cells
[154]. FGF-BP interacts also with the protein core of the pro-
angiogenic, FGF2-binding HSPG perlecan [155].
3.2. Serum components
3.2.1. Soluble FGFR1
A soluble form of the extracellular portion of FGFR1
(xcFGFR1) is present in blood, in the cerebral spinal fluid,
and in the vitreous fluid [see [156] and references therein].
Also, xcFGFR1 interacts with endothelial ECM [157].
xcFGFR1 binds FGF2 with an affinity that is lower than that
of the intact receptor (Table 1), but sufficient to prevent
FGF2/FGFR interaction when administered at high con-
centrations [158]. Also, xcFGFR1 may inhibit the biological
activity of FGF1, FGF2, and FGF3 by forming heterodimers
with cellular FGFR1, thus blocking the process of signal
transduction [159]. Nevertheless, the impact of xcFGFR1 on
angiogenesis remains to be investigated.
3.2.2. Fibrinogen
Fibrinogen is a 340 kDa glycoprotein found in blood or
immobilized on the blood vessel wall. Following blood
vessel injury, fibrinogen is converted to fibrin that represents
the temporary substrate for endothelial cell adhesion and
migration in the initial phases of the healing process.
Fibrin(ogen) binds FGF2, but not FGF1, with high affinity
[118] without affecting FGF2/FGFR1 interaction. Indeed,
FGF2 bound to immobilized fibrin(ogen) supports endothe-
lial cell proliferation [118] and protease production [160].
The FGF2-potentiating effect of fibrin(ogen) requires avb3that, in the presence of the adhesive protein, interacts with
FGFR1 [138]. These observations, together with the
capacity of fibrin(ogen) and FGF2 to bind avb3, underlay
the complex interplay among FGF, cell-surface receptors,
ECM components, and diffusible molecules.
3.2.3. a2-Macroglobulin
a2-Macroglobulin (a2M) is a 718 kDa homotetrameric
protein present in human plasma where it acts as a broad-
specific proteinase inhibitor. To exert its activity, a2M
undergoes major conformational changes that lead to the
activated form a2M
*. Both a2M and a2M
* bind a variety of
cytokines and growth factors, including FGF1, FGF2, FGF4,
and FGF6, but not FGF5, FGF7, FGF9, and FGF10 [161].
The binding of a2M to FGF2 occurs with high affinity
(Table 1) and is primarily hydrophobic in nature [162]. a2M
sequesters FGF2 in the extracellular environment and
inhibits its cell interaction, protease-inducing activity
[163] and mitogenic capacity [161]. Interestingly, both
TGF-b [162] and PDGF [163] compete with FGF2 for the
binding to a2M. Also, a2M competes with ECM compo-
nents for FGF2 interaction [161].
3.2.4. Pentraxin 3
Pentraxin 3 (PTX3) is a 45 kDa glycosylated protein
predominantly assembled in 10–20 mer multimers [164]. Its
COOH-terminal domain shares homology with the classic
short-pentraxin C-reactive protein whereas its NH2-terminal
portion does not show significant homology with any other
known protein [165]. PTX3 is synthesized and released by
activated mononuclear phagocytes and endothelial cells
[165] and acts as a soluble pattern recognition receptor with
unique functions in various physiopathological conditions.
These functions relay, at least in part, on the capacity of
PTX3 to bind different structures (see [166] and references
therein). PTX3 binds FGF2, but not FGF1 and FGF4, with
high affinity [166]. In endothelial cells, PTX3 prevents the
binding of FGF2 to cell surface FGFRs and HSPGs, with a
consequent inhibition of cell proliferation and migration,
and inhibits FGF2-dependent neovascularization in the
CAM assay. Also, PTX3 overexpression in FGF2-trans-
formed endothelial cells inhibits FGF2-dependent prolifera-
tion and invasion in vitro and tumorigenesis in vivo [166].
PTX3 exists both as a free or ECM-immobilized
molecule [167]. Relevant to this point, FGF2 and PTX3
retains their binding capacity independently of their free or
immobilized status [166]. Thus, as described for TSP-1, free
PTX3 may have access to ECM-bound FGF2 by acting as a
scavenger for the stored growth factor, whereas ECM-
associated PTX3 may act as a ‘‘FGF2 decoy’’, sequestering
the growth factor in an inactive form.
3.3. Cytokines
Platelet-derived growth factor BB (PDGF-BB) binds
FGF2 in a 1:2 stoichiometry [168]. This interaction may
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FGF2-dependent neovascularization [169].
The heparin-binding C-X-C chemokine platelet factor 4
(PF4) is a well known inhibitor of angiogenesis ([170] and
references therein). PF4 binds FGF1 [171] and FGF2 [170].
In endothelial cells, PF4 inhibits FGF2 interaction with
HSPGs and FGFR1, FGF2 internalization and mitogenic
activity [170]. Heparin stabilizes FGF2/PF4 interaction by
forming a ternary complex [172]. On the other hand, PF4
binds and masks cell surface or ECM-associated HSPGs,
hindering these receptors to FGF2 and FGF1 binding [173].4. FGF/FGFR system in tumor angiogenesis
4.1. Experimental tumors
Various tumor cell lines express FGF2 [174,175] and the
appearance of an angiogenic phenotype correlates with the
export of FGF2 during the development of fibrosarcoma in a
transgenic mouse model [176]. Antisense cDNAs for FGF2
and FGFR1 inhibit neovascularization and growth of human
melanomas in nude mice [177]. Also, the anti-angiogenic
activity of IFN-a/b appears to be related, at least in part, to
the capacity to down-regulate FGF2 expression [178]. These
data suggest that FGF2 production and release may occur in
vivo and may influence the growth and neovascularization of
tumor xenografts. Indeed, neutralizing anti-FGF2 antibodies
and soluble FGFRs affect tumor growth under defined
experimental conditions [179–182]. Accordingly, targeting
FGF-BP with specific ribozymes inhibits the growth and
vascularization of xenografted tumors in mice [154] despite
the high levels of VEGF produced by these cells [183].
Interestingly, FGF-BP may exert its biological function via a
paracrine stimulation on both tumor and endothelial cells
[184]. Indeed, given the pleiotropic activity of FGFs, it is not
always possible to dissociate the effect of FGFs on tumor
angiogenesis from those exerted directly on tumor cells. For
instance, S115 breast cancer cells transfected with FGF8b,
but not with FGF8a or FGF8e, originate highly vascularized
tumors when injected in nude mice. However, FGF8b also
affect their ancorage-independent growth in vitro in an
autocrine manner [17]. Similar results were reported for
FGF4-transfected human breast carcinoma cells [185]. Also,
inhibition of FGF/FGFR system in glioma cells by dominant
negative FGFR transfection [99] or in prostate cancer cells
by fgf2 gene knockout [186] results in inhibition of tumor
growth by both angiogenesis-dependent and -independent
mechanisms.
Relevant to this point, constitutive [187,188] or tetra-
cycline-regulated [189] FGF2 overexpression causes a
significant increase in the angiogenic activity and tumori-
genic capacity of a VEGF-producing human endometrial
adenocarcinoma cell line without affecting tumor cell
proliferation in vitro [189]. These data suggest that
modulation of FGF2 expression may indeed have a directeffect on angiogenesis and may allow a fine tuning of tumor
vascularity even in the presence of VEGF (see above).
Accordingly, simultaneous expression of FGF2 and VEGF
in these tumor cells results in fast growing tumor xenografts
in nude mice characterized by high blood vessel density,
patency and permeability [106]. Inhibition of FGF2
production causes a significant decrease in the growth
and vascularization of these lesions, without affecting vessel
patency and permeability, pericyte recruitment, tumor
necrosis, and oxygenation (as evaluated by HIF-1a
immunostaining). In contrast, the decrease in tumor growth
and vascularization consequent to antisense VEGF cDNA
transfection is also paralleled by a significant decrease in
monocyte infiltrate, pericyte organization, vascular patency,
and permeability. This results in an increase in HIF-1a
immunoreactivity and tumor necrosis. An additional
inhibitory effect is exerted by FGF2 down-regulation in
antisense VEGF cDNA transfected lesions. Thus, FGF2 and
VEGF factors exert a synergistic effect on tumor blood
vessel density in this model. However, FGF2 and VEGF
differently affect blood vessel maturation and functionality
(see also [112]).
In keeping with these observations, adenoviral expression
of a soluble form of VEGFR-1 in spontaneous b-cell
pancreatic tumors in Rip1 Tag2 mice affected the initial
stages of tumor angiogenesis whereas soluble FGFR2
appeared to impair the maintenance of tumor angiogenesis.
The combination of the two soluble receptors exerted a
synergistic effect [182]. In addition, expression of a
dominant-negative FGFR1 in the retina of Tryp1-Tag mice
that develop early vascularized tumors of the retinal pigment
epithelium results in a significant decrease in tumor burden
and vascularity [190].
4.2. Human tumors
The possibility that FGFs may play a role in human tumor
vascularization represents an important issue in FGF biology
and for the development of anti-angiogenic therapies.
Numerous studies have attempted to establish a correlation
between intratumoral levels of FGF2 mRNA or protein and
intratumoral microvessel density (MVD) in cancer patients.
Table 2 summarizes the results from 53 independent studies
that investigated the correlation between intratumoral FGF2
levels and MVD and between these two parameters and
cancer progression/prognosis. Clearly, the bulk of data
highlight a marked heterogeneity among different tumors
and also among different studies within the same tumor type.
With a few exceptions (e.g. melanomas) FGF2 levels do not
correlate persistently with MVD. This is in sharp contrast
with what observed for VEGF levels that more systemically
correlate with MVD.
It is interesting to note that in some tumor types (e.g.
breast and hepatocellular carcinomas) intratumoral levels of
FGF2 correlate with the clinical outcome but not with MVD.
As stated above, the pleiotropic activity of FGFs may affect
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Table 2
Correlation between intratumor FGF2 or VEGF levels with tumor vascularity (MVD) or clinical outcome
Tumor type FGF2 levels vs. MVD FGF2 levels vs. clinical outcomea VEGF levels vs. MVDb
Astrocytoma +  N.D. + +
Basal cell carcinoma   +
Bladder carcinoma + + + +
Breast carcinoma +     + + + + + +
Cardiac myxoma + N.D. N.D.
Colorectal adenocarcinoma    + + +
Epidermoid lung carcinoma  + +
Gastric carcinoma   +
Glioma + +  +   + +
Hepatocellular carcinoma  + + +
Laringeal adenocarcinoma   +
Leiomyoma  N.D. +
Leiomyosarcoma  N.D. +
Melanoma + + + + + N.D.
Meningioma      
Mesotelioma + + +
Non-Hodgkin’s lymphoma  + N.D.
Non-small cell lung carcinoma  + N.D.
Pancreatic adenocarcinoma + +  + +  + + +
Parathyroid adenoma +  N.D
Pituitary adenoma + N.D. +
Prostatic adenocarcinoma + +  + + + +
Pulmonary adenocarcinoma + N.D. +
Renal carcinoma   +  
Squamous cell carcinoma + + +  +    + + +
Thymoma   N.D.
+: correlation; : no correlation; N.D.: not determined. Multiple symbols refer to distinct studies on the same tumor type.
a Clinical features analysed in the various studies were: grading/staging, metastatic status, disease recurrence, poor prognosis.
b Only those studies in which VEGF was directly compared to FGF2 were included.both tumor vasculature and tumor parenchyma. Thus, at
variance with the more endothelial-specific VEGF, FGF2 (as
well as other FGFs) may contribute to cancer progression
not only by inducing neovascularization, but also by acting
directly on tumor cells. Accordingly, the co-expression of
FGF7/KGF and its receptor FGFR2 IIIb/KGFR correlates
with the high proliferative activity and poor prognosis in
lung adenocarcinoma [191].
Evaluation of MVD may have prognostic significance in
solid tumors [192,193], lymphomas [194], and leukemia
[195]. Quantification of the angiogenic proteins in body
fluids may represent an indirect, non-invasive way to
measure angiogenic activity in cancer patients. Serum
concentration of angiogenic factors increases with tumor
progression [196] and decreases in response to treatment and
long-term disease control [197]. Thus, apart from providing
prognostic information in early detection of primary tumors
or to follow tumor progression, measurement of these
circulating factors may be used to monitor tumor regression
during therapy and for the selection of patients at high risk of
recurrences after treatment [198].
Moreover, the prognostic significance of FGF levels in
biological fluids of cancer patients is controversial. Early
studies showed that elevated levels of FGF2 in urine samples
collected from 950 patients having a wide variety of solid
tumors, leukemia or lymphoma were significantly correlated
with the status and the extent of disease [199]. However, noassociation between increased serum levels of FGF2 and
tumor type was observed in later studies on a large spectrum
of metastatic carcinomas even though two-thirds of the
patients showing progressive disease had increasing serum
levels of the angiogenic factor compared with less than one-
tenth of the patients showing response to therapy [200]. The
clinical significance of circulating FGF2 in individual types
of cancer has been recently reviewed [201]. Briefly, the
levels of circulating FGF2 may have prognostic significance
in head and neck cancer, lymphoma, leukemia, prostate
carcinoma, and soft tissue sarcoma but they do not correlate
with breast cancer progression and their significance in
colorectal carcinoma is unclear. Also, after an encouraging
report about a positive correlation between MVD and
cerebrospinal fluid FGF2 in children with brain tumors
[202], FGF2 levels in body fluids do not always reflect tumor
vascularity. Moreover, serum FGF2 may not entirely derive
from the neoplastic tissue in cancer patients [203].
In conclusion, clinical reports have not established yet a
clear relationship among FGFs, tumor angiogenesis, and
tumor progression/prognosis. Further studies assessing the
correlation between FGF levels at the tumor site and/or in
body fluids and MVD are eagerly awaited before these
growth factors, as well as other angiogenic factors, can be
used as prognostic indicators, surrogate markers of
angiogenesis in cancer patients, and as targets for angiostatic
therapies.
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Inflammation is the response of a vascularized tissue to
sub-lethal injury, designed to destroy or inactivate invading
pathogens, remove waste and debris, and permit restoration
of normal function, either through resolution or repair.
Inflammation may promote FGF-dependent angiogenesis
(Fig. 4). Inflammatory cells, including mononuclear
phagocytes [204,205], CD4+ and CD8+ T lymphocytes
[206,207], and mast cells [208] can express FGF2. More-
over, osmotic shock and shear stress induce the release of
FGF2 from endothelial cells [209,210]. FGF2 production
and release from endothelial cells are also triggered by
IFN-a plus IL-2 [211], IL-1b [212], and nitric oxide (NO)
[213]. NO is produced by vascular endothelium following
stimulation by cytokines, bacterial endotoxins, inflamma-
tory mediators, neuropeptides, and shear stress [214]. Even
though FGF2-induced angiogenesis can occur indepen-
dently of NO synthesis [215], the pro-angiogenic effects
exerted by NO and NO-inducing molecules are due, at least
in part, to the NO-mediated FGF2 upregulation in
endothelial cells [216]. Thus, inflammatory mediators can
activate the endothelium to synthesize and release FGFs
that, in turn, will stimulate angiogenesis by an autocrineFig. 4. Schematic representation of the interplay between FGFs and inflammation.
different mechanisms. In turn, FGFs can modulate various steps of the inflamm
activation) on inflammatory leukocytes. This results in the amplification of the amechanism of action (Fig. 4). On the other hand, PTX3,
synthesized locally by endothelial cells in response to IL-1b
and TNF-a, binds FGF2 and acts as a natural angiogenesis
inhibitor (see above), thus allowing a fine tuning of FGF2
pro-angiogenic activity in inflammation.
The inflammatory response may also cause cell damage,
fluid and plasma protein exudation, and hypoxia. Endothe-
lial cell damage results in increased FGF2 production and
release [217]; exudated fibrin(ogen) can bind FGF2 and
enhances its biological activity (see above); hypoxia
upregulates the production of angiogenic growth factor,
including VEGF [218] and FGF2 [204]. Furthermore,
hypoxia increases endothelial cell responsiveness to FGF2
by promoting HSPG synthesis [219] and upregulates FGF2
production also in vascular pericytes [220].
Conversely, by interacting with endothelial cells, FGF2
may amplify the inflammatory and angiogenic response by
inducing vasoactive effects and the recruitment of an
inflammatory infiltrate (Fig. 4). Indeed, FGF2, but not FGF1,
causes vasodilation of coronary arterioles via an increase in
NO production [221]. FGFs can also induce vascular
permeability indirectly, by upregulating VEGF and pro-
teases (see above), and directly, as suggested for FGF2 and
FGF5 [222]. Transient exposure to FGF1 and FGF2Several inflammatory mediators can affect the biological activity of FGFs by
atory process by acting directly (or indirectly following endothelial cell
ngiogenic response triggered by FGFs on endothelial cells.
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1 and VCAM-1 in endothelial cells, increasing polymorpho-
nuclear leukocyte adhesion and transendothelial migration
[223]. Also, FGF2-stimulated endothelial cells upregulate the
synthesis of various chemoattractants, including VEGF, that
may exert a chemotactic activity on monocytes [224], the
angiogenic/monocyte chemotactic protein osteopontin [225],
monocyte chemoattractant protein-1 [107,226], and the pro-
angiogenic cyclooxygenase-2 [227]. Moreover, FGF2 exerts a
direct chemotactic effect on monocytes (Presta, unpublished
observations). Finally, in agreement with a possible role of
inflammatory cells in FGF2-mediated neovascularization, a
significant inhibition of the angiogenic response to FGF2 is
observed in neutropenic mice [228].
Even though these experimental evidences point to a
possible loop of amplification of the angiogenic response
triggered by FGF2 and mediated by the inflammatory
infiltrate, long-lasting exposure to FGF2 down-regulates
cytokine-induced ICAM-1, VECAM-1, and E-selectin
expression in endothelial cells. Consequently, polymorpho-
nuclear leukocyte adhesion and transendothelial migration
are reduced [223]. Similarly, monocyte/macrophages adhe-
sion to endothelium and the chemotactic response to various
chemokines are markedly inhibited by long-term stimula-
tion by FGF1 or FGF2, but not by VEGF [229]. Also, FGF2
suppress transendothelial migration of CD4+ T-lymphocytes
[230] and tissue factor expression in endothelial cells [231].
These observations suggest that the pro- or anti-inflamma-
tory activity of FGFs may be contextual and may explain, at
least in part, the reduced leukocyte adhesion and transen-
dothelial migration observed in experimental tumors [232]
that, nevertheless, are characterized by the presence of pro-
angiogenic tumor-associated macrophages [233].6. FGFs and therapeutic angiogenesis
Therapeutic angiogenesis represents a possible approach
to the treatment of severe ischemic diseases in patients with
coronary (CAD) or peripheral (PAD) artery injury. Aim of
this therapy is to restore and maintain tissue perfusion by
increasing the number of collateral blood vessels within the
ischemic territories following the delivery of specific
angiogenic growth factors. Different delivery methods,
including intravenous, intracoronary, intramyocardial and
intrapericardial routes, are normally used to administer
angiogenic factors either as recombinant proteins or by gene
transfer using naked DNA or vectors that encode the gene to
be incorporated into the target cells.
Among the different members of the FGF family, FGF1,
FGF2, FGF4, and FGF5 have been more widely investigated,
with particular emphasis to FGF2. For instance, in swine and
canine models of coronary occlusion, intracoronary FGF2
administration or local injection in the myocardium can reduce
scar size, preserve myocardial function, and increase number
of blood vessels (reviewed in [234]).In CAD patients, slow-release FGF2 capsules implanted
in the myocardium in a phase I clinical trial caused a
significant reduction in size of the ischemic region and
treated patients had more freedom from angina recurrence
than controls [235,236]. Also, single-bolus intracoronary
FGF2 infusion showed transient beneficial effects, including
reduction of angina symptoms, increase of treadmill
tolerance and quality of life [237]. Transient beneficial
effects were observed also in the phase II trial FIRST in
which FGF2 was administered via intracoronary infusion
[238]. In PAD patients, a positive response was observed in a
phase I trial in which patients with symptoms of
claudications and advanced peripheral arterial disease
where given intra-arterial FGF2 infusion [239]. An early,
transient improvement in performance was observed also in
the phase II trial TRAFFIC in which patients with infra-
inguinal atherosclerosis and claudication received a bilateral
intra-arterial infusion of FGF2 [240].
Experience with FGF1 is more limited. Early studies
using a recombinant FGF1 protein reported no beneficial
effects in a dog model of myocardial ischemia probably due
to the short protein half-life. Indeed, administration of a
FGF1 mutant with prolonged half-life showed an augmenta-
tion of blood flow and function in ischemic porcine
myocardium [241]. Similar beneficial effects were observed
in a hindlimb ischemia rabbit model using a single
intramuscolar dose of naked DNA encoding FGF1 [242].
Phase I clinical trials have shown some beneficial effects
following FGF1 protein injection in ischemic myocardium
[243]. Similarly, intramuscular FGF1 gene injection in PAD
patients resulted in a transient beneficial effect that was not
sustained at 6 months [244].
The angiogenic potency of FGF4 and FGF5 was
evaluated by gene therapy using an adenoviral vector in
the rabbit hindlimb [94,245] and in the pig myocardium
[246]. Adenovirus-delivered FGF4 was tested in two phase I
clinical trials (AGENT and AGENT 2), involving patients
with chronic stable angina. No beneficial effects were
observed in both trials [246,247].
In conclusion, current clinical experience in ischemic
disease suggest that FGF-based angiogenic therapy may
represent a promising treatment for patients. However,
further investigation is required to solve mayor problems
that are critical to successful therapy: identification of the
most effective delivery approach, proper selection of
patients, timing and dosage of angiogenic factors used
alone or in combinations [248].Acknowledgements
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